English

Eloxx Pharmaceuticals, Inc.

EDGAR

ELOX Current report (8-K) · filed 2026-10-22

Annual consolidated revenue for 2026: about USD 0, using the latest reported figures. The previous period, 2025, was about USD 6.359M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest fiscal year

Revenue

0 USD

2026 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating margin

-38.81%

2025 · %

Exact inputs and evidence

Operating Income: -2468000 USD Source
Revenue: 6359000 USD Source

Operating cash flow

-6.33 million USD

2026 · USD

Exact inputs and evidence

Operating Cash Flow: -6327000 USD Source

Cash and cash equivalents: 62 million USD 2026-06-30 Source
Exact value

61960000 USD
Long-term debt including current maturities: 1 million USD 2025-12-31 Source
Exact value

1000000 USD
Shares outstanding: 4.04 million shares 2026-06-30 Source
Exact value

4036398 shares

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Capital expenditure

0 USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Capital expenditure: 66000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 66000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 0 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 0 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 0 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 0 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 0 USD · 2023-01-01 – 2023-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-22.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 9 of 11 periods available· newest 2022-12-31
Total assets: 3 of 11 periods available· newest 2025-12-31
Total liabilities: 3 of 11 periods available· newest 2025-12-31
Current assets: 3 of 11 periods available· newest 2025-12-31
Current liabilities: 3 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2025-12-31
Shares outstanding: 3 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-100%

Prior period

USD 6.36 million

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 6359000 = -6359000 USD

6359000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Eloxx Pharmaceuticals, Inc. · 2025-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Year-over-year change in Revenue: -6359000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/elox-20251231.htm#2405490 Filing: 000119312526108687 Input fundies:Revenue: 6359000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/elox-20251231.htm#2407090 Filing: 000119312526108687
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 2.85 million

Prior period

−USD 3.14 million

2024-01-01 – 2024-12-31
Current period

−USD 6 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-5995000 − -3143000 = -2852000 USD

-3143000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-5995000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Eloxx Pharmaceuticals, Inc. · 2025-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Year-over-year change in Net income: -2852000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -5995000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/elox-20251231.htm#4023753 Filing: 000119312526108687 Input fundies:NetIncome: -3143000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/elox-20251231.htm#4025499 Filing: 000119312526108687
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 1.61 million

Prior period

−USD 4.72 million

2024-01-01 – 2024-12-31
Current period

−USD 6.33 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-6327000 − -4715000 = -1612000 USD

-4715000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-6327000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Eloxx Pharmaceuticals, Inc. · 2025-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Year-over-year change in Operating cash flow: -1612000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -6327000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/elox-20251231.htm#2791519 Filing: 000119312526108687 Input fundies:OperatingCashFlow: -4715000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/elox-20251231.htm#2793398 Filing: 000119312526108687
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2026 2025-01-01 – 2025-12-31

Revenue USD 0
Operating costs Derived USD 6.44 million
Operating income −USD 6.44 million
Tax, interest and other Derived −USD 443,000
Net income −USD 6 million

Cash

Operating cash flow −USD 6.33 million
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2024 Not shown: operating income or net income is not reported.
2025 Operating loss: operating costs were 139% of revenue.
2026 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2024 2023-01-01 – 2023-12-31	0	17288000 Derived	-17288000	-234000 Derived	-17054000	Unavailable	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -17288000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -17054000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -14341000 USD Inspect Operating Cash Flow Open source
2025 2024-01-01 – 2024-12-31	6359000	8827000 Derived	-2468000	675000 Derived	-3143000	Unavailable	Source 2024-01-01 – 2024-12-31: 6359000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -2468000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -3143000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -4715000 USD Inspect Operating Cash Flow Open source
2026 2025-01-01 – 2025-12-31	0	6438000 Derived	-6438000	-443000 Derived	-5995000	Unavailable	Source 2025-01-01 – 2025-12-31: 0 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -6438000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -5995000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -6327000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2026

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20242023-12-31	Revenue	0	Revenue: 0 Open source
20252024-12-31	Revenue	6359000	Revenue: 6359000 Open source
20262025-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2026

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20242023-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20252024-12-31	Year over year	No prior comparable period	Revenue: 6359000 Open source Revenue: 0 Open source
20262025-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 6359000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -38.8% 2025

Net margin -49.4% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20242023-12-31	Operating margin	Not reported	Operating Income: -17288000 Open source Revenue: 0 Open source
20252024-12-31	Operating margin	-38.8%	Operating Income: -2468000 Open source Revenue: 6359000 Open source
20262025-12-31	Operating margin	Not reported	Operating Income: -6438000 Open source Revenue: 0 Open source
20242023-12-31	Net margin	Not reported	Net Income: -17054000 Open source Revenue: 0 Open source
20252024-12-31	Net margin	-49.4%	Net Income: -3143000 Open source Revenue: 6359000 Open source
20262025-12-31	Net margin	Not reported	Net Income: -5995000 Open source Revenue: 0 Open source
20242023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -14341000 Open source
20252024-12-31	Free cash flow margin	Not reported	Revenue: 6359000 Open source Operating Cash Flow: -4715000 Open source
20262025-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -6327000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -6.3M 2026

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20242023-12-31	Operating cash flow	-14341000	Operating Cash Flow: -14341000 Open source
20252024-12-31	Operating cash flow	-4715000	Operating Cash Flow: -4715000 Open source
20262025-12-31	Operating cash flow	-6327000	Operating Cash Flow: -6327000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20242023-12-31	Free cash flow	Unavailable	Operating Cash Flow: -14341000 Open source
20252024-12-31	Free cash flow	Unavailable	Operating Cash Flow: -4715000 Open source
20262025-12-31	Free cash flow	Unavailable	Operating Cash Flow: -6327000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

325.9% 2026

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20242023-12-31	Liabilities / assets	1,420%	Total Liabilities: 24311000 Open source Total Assets: 1712000 Open source
20252024-12-31	Liabilities / assets	917.7%	Total Liabilities: 27311000 Open source Total Assets: 2976000 Open source
20262025-12-31	Liabilities / assets	325.9%	Total Liabilities: 17177000 Open source Total Assets: 5270000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.31× 2026

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20242023-12-31	Current assets / current liabilities	0.07×	Current Assets: 1548000 Open source Current Liabilities: 22697000 Open source
20252024-12-31	Current assets / current liabilities	0.11×	Current Assets: 2976000 Open source Current Liabilities: 27311000 Open source
20262025-12-31	Current assets / current liabilities	0.31×	Current Assets: 5270000 Open source Current Liabilities: 17177000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2016-07-01 – 2017-06-30	−USD 933,577 Exact value Exact value: -933577 USD 2016-07-01 – 2017-06-30: -933577 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eloxx Pharmaceuticals, Inc. · 2017-06-30 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Net Income: -933577 USD Concept: fundies:NetIncome Period: 2016-07-01 to 2017-06-30 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3ANetIncome&period=2017-06-30&surface=latest&period_type=duration&start=2016-07-01&unit=USD&dimensions= Input fundies:NetIncome: -933577 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000114420417059104/svon-20170930.xml#41054 Filing: 000114420417059104 The citation records this snapshot. The page link may show a newer release later.	−USD 1.93 million Exact value Exact value: -1925110 USD 2016-07-01 – 2017-06-30: -1925110 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eloxx Pharmaceuticals, Inc. · 2017-06-30 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Operating Cash Flow: -1925110 USD Concept: fundies:OperatingCashFlow Period: 2016-07-01 to 2017-06-30 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3AOperatingCashFlow&period=2017-06-30&surface=latest&period_type=duration&start=2016-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1925110 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000114420417052475/svon-20170630.xml#120621 Filing: 000114420417052475 The citation records this snapshot. The page link may show a newer release later.	USD 2,500 Exact value Exact value: 2500 USD 2016-07-01 – 2017-06-30: 2500 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Eloxx Pharmaceuticals, Inc. · 2017-06-30 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Capital Expenditure: 2500 USD Concept: fundies:CapitalExpenditure Period: 2016-07-01 to 2017-06-30 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3ACapitalExpenditure&period=2017-06-30&surface=latest&period_type=duration&start=2016-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2500 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000114420417052475/svon-20170630.xml#121439 Filing: 000114420417052475 The citation records this snapshot. The page link may show a newer release later.	−USD 1.93 million Calculation and evidence -1925110 − 2500 USD Exact free cash flow: -1927610 USD 2016-07-01 – 2017-06-30: -1925110 USD · Inspect Operating Cash Flow · Source 2016-07-01 – 2017-06-30: 2500 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Eloxx Pharmaceuticals, Inc. · 2017-06-30 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Free cash flow: -1927610 USD Concept: free-cash-flow Period: 2016-07-01 to 2017-06-30 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1925110 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000114420417052475/svon-20170630.xml#120621 Filing: 000114420417052475 Input fundies:CapitalExpenditure: 2500 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000114420417052475/svon-20170630.xml#121439 Filing: 000114420417052475 The citation records this snapshot. The page link may show a newer release later.
2018 2017-01-01 – 2017-12-31	−USD 21.21 million Exact value Exact value: -21214000 USD 2017-01-01 – 2017-12-31: -21214000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eloxx Pharmaceuticals, Inc. · 2017-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Net Income: -21214000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -21214000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459020009148/elox-20191231.xml#120430 Filing: 000156459020009148 The citation records this snapshot. The page link may show a newer release later.	−USD 15.94 million Exact value Exact value: -15935000 USD 2017-01-01 – 2017-12-31: -15935000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eloxx Pharmaceuticals, Inc. · 2017-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Operating Cash Flow: -15935000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15935000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459020009148/elox-20191231.xml#161691 Filing: 000156459020009148 The citation records this snapshot. The page link may show a newer release later.	USD 237,000 Exact value Exact value: 237000 USD 2017-01-01 – 2017-12-31: 237000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Eloxx Pharmaceuticals, Inc. · 2017-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Capital Expenditure: 237000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 237000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459020009148/elox-20191231.xml#162766 Filing: 000156459020009148 The citation records this snapshot. The page link may show a newer release later.	−USD 16.17 million Calculation and evidence -15935000 − 237000 USD Exact free cash flow: -16172000 USD 2017-01-01 – 2017-12-31: -15935000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 237000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Eloxx Pharmaceuticals, Inc. · 2017-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Free cash flow: -16172000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15935000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459020009148/elox-20191231.xml#161691 Filing: 000156459020009148 Input fundies:CapitalExpenditure: 237000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459020009148/elox-20191231.xml#162766 Filing: 000156459020009148 The citation records this snapshot. The page link may show a newer release later.
2019 2018-01-01 – 2018-12-31	−USD 47.19 million Exact value Exact value: -47185000 USD 2018-01-01 – 2018-12-31: -47185000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eloxx Pharmaceuticals, Inc. · 2018-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Net Income: -47185000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -47185000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459021012703/elox-10k_20201231.htm#2800783 Filing: 000156459021012703 The citation records this snapshot. The page link may show a newer release later.	−USD 31.37 million Exact value Exact value: -31367000 USD 2018-01-01 – 2018-12-31: -31367000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eloxx Pharmaceuticals, Inc. · 2018-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Operating Cash Flow: -31367000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -31367000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459021012703/elox-10k_20201231.htm#1956085 Filing: 000156459021012703 The citation records this snapshot. The page link may show a newer release later.	USD 235,000 Exact value Exact value: 235000 USD 2018-01-01 – 2018-12-31: 235000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Eloxx Pharmaceuticals, Inc. · 2018-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Capital Expenditure: 235000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 235000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459021012703/elox-10k_20201231.htm#1977747 Filing: 000156459021012703 The citation records this snapshot. The page link may show a newer release later.	−USD 31.6 million Calculation and evidence -31367000 − 235000 USD Exact free cash flow: -31602000 USD 2018-01-01 – 2018-12-31: -31367000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 235000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Eloxx Pharmaceuticals, Inc. · 2018-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Free cash flow: -31602000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -31367000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459021012703/elox-10k_20201231.htm#1956085 Filing: 000156459021012703 Input fundies:CapitalExpenditure: 235000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459021012703/elox-10k_20201231.htm#1977747 Filing: 000156459021012703 The citation records this snapshot. The page link may show a newer release later.
2020 2019-01-01 – 2019-12-31	−USD 50.87 million Exact value Exact value: -50874000 USD 2019-01-01 – 2019-12-31: -50874000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eloxx Pharmaceuticals, Inc. · 2019-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Net Income: -50874000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -50874000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459022012683/elox-10k_20211231.htm#2762849 Filing: 000156459022012683 The citation records this snapshot. The page link may show a newer release later.	−USD 39.39 million Exact value Exact value: -39391000 USD 2019-01-01 – 2019-12-31: -39391000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eloxx Pharmaceuticals, Inc. · 2019-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Operating Cash Flow: -39391000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -39391000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459022012683/elox-10k_20211231.htm#1933129 Filing: 000156459022012683 The citation records this snapshot. The page link may show a newer release later.	USD 40,000 Exact value Exact value: 40000 USD 2019-01-01 – 2019-12-31: 40000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Eloxx Pharmaceuticals, Inc. · 2019-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Capital Expenditure: 40000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 40000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459022012683/elox-10k_20211231.htm#1960066 Filing: 000156459022012683 The citation records this snapshot. The page link may show a newer release later.	−USD 39.43 million Calculation and evidence -39391000 − 40000 USD Exact free cash flow: -39431000 USD 2019-01-01 – 2019-12-31: -39391000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 40000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Eloxx Pharmaceuticals, Inc. · 2019-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Free cash flow: -39431000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -39391000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459022012683/elox-10k_20211231.htm#1933129 Filing: 000156459022012683 Input fundies:CapitalExpenditure: 40000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459022012683/elox-10k_20211231.htm#1960066 Filing: 000156459022012683 The citation records this snapshot. The page link may show a newer release later.
2021 2020-01-01 – 2020-12-31	−USD 34.58 million Exact value Exact value: -34577000 USD 2020-01-01 – 2020-12-31: -34577000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eloxx Pharmaceuticals, Inc. · 2020-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Net Income: -34577000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -34577000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459022012683/elox-10k_20211231.htm#2761094 Filing: 000156459022012683 The citation records this snapshot. The page link may show a newer release later.	−USD 28.17 million Exact value Exact value: -28166000 USD 2020-01-01 – 2020-12-31: -28166000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eloxx Pharmaceuticals, Inc. · 2020-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Operating Cash Flow: -28166000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28166000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000156459022012683/elox-10k_20211231.htm#1931165 Filing: 000156459022012683 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2021-01-01 – 2021-12-31	−USD 66.73 million Exact value Exact value: -66727000 USD 2021-01-01 – 2021-12-31: -66727000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eloxx Pharmaceuticals, Inc. · 2021-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Net Income: -66727000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -66727000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000095017023011360/elox-20221231.htm#2788111 Filing: 000095017023011360 The citation records this snapshot. The page link may show a newer release later.	−USD 35 million Exact value Exact value: -35001000 USD 2021-01-01 – 2021-12-31: -35001000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eloxx Pharmaceuticals, Inc. · 2021-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Operating Cash Flow: -35001000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35001000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000095017023011360/elox-20221231.htm#1931245 Filing: 000095017023011360 The citation records this snapshot. The page link may show a newer release later.	USD 89,000 Exact value Exact value: 89000 USD 2021-01-01 – 2021-12-31: 89000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Eloxx Pharmaceuticals, Inc. · 2021-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Capital Expenditure: 89000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 89000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000095017023011360/elox-20221231.htm#1939169 Filing: 000095017023011360 The citation records this snapshot. The page link may show a newer release later.	−USD 35.09 million Calculation and evidence -35001000 − 89000 USD Exact free cash flow: -35090000 USD 2021-01-01 – 2021-12-31: -35001000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 89000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Eloxx Pharmaceuticals, Inc. · 2021-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Free cash flow: -35090000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35001000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000095017023011360/elox-20221231.htm#1931245 Filing: 000095017023011360 Input fundies:CapitalExpenditure: 89000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000095017023011360/elox-20221231.htm#1939169 Filing: 000095017023011360 The citation records this snapshot. The page link may show a newer release later.
2023 2022-01-01 – 2022-12-31	−USD 36.07 million Exact value Exact value: -36065000 USD 2022-01-01 – 2022-12-31: -36065000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eloxx Pharmaceuticals, Inc. · 2022-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Net Income: -36065000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -36065000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000095017023011360/elox-20221231.htm#2785856 Filing: 000095017023011360 The citation records this snapshot. The page link may show a newer release later.	−USD 31.85 million Exact value Exact value: -31845000 USD 2022-01-01 – 2022-12-31: -31845000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eloxx Pharmaceuticals, Inc. · 2022-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Operating Cash Flow: -31845000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -31845000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000095017023011360/elox-20221231.htm#1928922 Filing: 000095017023011360 The citation records this snapshot. The page link may show a newer release later.	USD 66,000 Exact value Exact value: 66000 USD 2022-01-01 – 2022-12-31: 66000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Eloxx Pharmaceuticals, Inc. · 2022-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Capital Expenditure: 66000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 66000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000095017023011360/elox-20221231.htm#1937015 Filing: 000095017023011360 The citation records this snapshot. The page link may show a newer release later.	−USD 31.91 million Calculation and evidence -31845000 − 66000 USD Exact free cash flow: -31911000 USD 2022-01-01 – 2022-12-31: -31845000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 66000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Eloxx Pharmaceuticals, Inc. · 2022-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Free cash flow: -31911000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -31845000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000095017023011360/elox-20221231.htm#1928922 Filing: 000095017023011360 Input fundies:CapitalExpenditure: 66000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000095017023011360/elox-20221231.htm#1937015 Filing: 000095017023011360 The citation records this snapshot. The page link may show a newer release later.
2024 2023-01-01 – 2023-12-31	−USD 17.05 million Exact value Exact value: -17054000 USD 2023-01-01 – 2023-12-31: -17054000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eloxx Pharmaceuticals, Inc. · 2023-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Net Income: -17054000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17054000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/elox-20251231.htm#4027245 Filing: 000119312526108687 The citation records this snapshot. The page link may show a newer release later.	−USD 14.34 million Exact value Exact value: -14341000 USD 2023-01-01 – 2023-12-31: -14341000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eloxx Pharmaceuticals, Inc. · 2023-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Operating Cash Flow: -14341000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14341000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/elox-20251231.htm#2795277 Filing: 000119312526108687 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2024-01-01 – 2024-12-31	−USD 3.14 million Exact value Exact value: -3143000 USD 2024-01-01 – 2024-12-31: -3143000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eloxx Pharmaceuticals, Inc. · 2024-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Net Income: -3143000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3143000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/elox-20251231.htm#4025499 Filing: 000119312526108687 The citation records this snapshot. The page link may show a newer release later.	−USD 4.72 million Exact value Exact value: -4715000 USD 2024-01-01 – 2024-12-31: -4715000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eloxx Pharmaceuticals, Inc. · 2024-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Operating Cash Flow: -4715000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4715000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/elox-20251231.htm#2793398 Filing: 000119312526108687 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2026 2025-01-01 – 2025-12-31	−USD 6 million Exact value Exact value: -5995000 USD 2025-01-01 – 2025-12-31: -5995000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eloxx Pharmaceuticals, Inc. · 2025-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Net Income: -5995000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5995000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/elox-20251231.htm#4023753 Filing: 000119312526108687 The citation records this snapshot. The page link may show a newer release later.	−USD 6.33 million Exact value Exact value: -6327000 USD 2025-01-01 – 2025-12-31: -6327000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eloxx Pharmaceuticals, Inc. · 2025-12-31 Eloxx Pharmaceuticals, Inc. (edgar:1035354) Operating Cash Flow: -6327000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:05:11Z Snapshot: c2f080e5f58d41164088378f339e12fc423e9e1aaed033e74009b108e7e1b995 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1035354/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6327000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/elox-20251231.htm#2791519 Filing: 000119312526108687 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

193 filings · 3,184 latest values · 3,184 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001035354, 1035354, ELOX, SNT, SNTI, SVON, edgar:1035354

Also known as ELOXX PHARMACEUTICALS, INC., Eloxx Pharmaceuticals, Inc., NAVA LEISURE USA INC, SENESCO TECHNOLOGIES INC, Sevion Therapeutics, Inc.

Eloxx Pharmaceuticals, Inc.

Latest fiscal year

Revenue

Operating margin

Operating cash flow

Trailing twelve months

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2026 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation